Re-programming tumour cell metabolism to treat cancer: No lone target for lonidamine

Biochemical Journal

Volumn 473, Issue 11, 2016, Pages 1503-1506

  Bhutia, Yangzom D ^a   Babu, Ellappan ^a   Ganapathy, Vadivel ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

Hexokinase II; Lonidamine; Metabolism; Monocarboxylate transporters; Pyruvate carrier.

Indexed keywords

HEXOKINASE II; LACTATE DEHYDROGENASE; LONIDAMINE; MONOCARBOXYLATE TRANSPORTER; PHOSPHOTRANSFERASE; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INDAZOLE DERIVATIVE;

CELL METABOLISM; GLYCOLYSIS; HUMAN; LOSS OF FUNCTION MUTATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NEOPLASM; NUCLEAR REPROGRAMMING; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUMOR CELL; DRUG EFFECTS; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; GLYCOLYSIS; HUMANS; INDAZOLES; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84975108548     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BCJ20160068     Document Type: Review

References (31)

1. Kroemer, G. and Pouyssegur, J. (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482
2. Galluzzi, L., Kepp, O., Vander Heiden, M.G. and Kroemer, G. (2013) Metabolic targets for cancer therapy. Nat. Rev. Drug Discov. 12, 829-846
3. Jang, M., Kim, S.S. and Lee, J. (2013) Cancer cell metabolism: implications for therapeutic targets. Exp. Mol. Med. 45,e45
4. Ganapathy, V., Thangaraju, M. and Prasad, P.D. (2009) Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 121, 29-40
5. Nowicki, S. and Gottlieb, E. (2015) Oncometabolites: tailoring our genes. FEBS J. 282, 2796-2805
6. Bhat, T.A., Kumar, S., Chaudhary, A.K., Yadav, N. and Chandra, D. (2015) Restoration of mitochondria function as a target for cancer therapy. Drug. Discov. Today 20, 635-643
7. Miao, P., Sheng, S., Sun, X., Liu, J. and Huang, G. (2013) Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy. IUBMB Life 65, 904-910
8. Chi, H. (2012) Regulation and function of mTOR signaling in T cell fate decisions. Nat. Rev. Immunol. 12, 325-338
9. Waickman, A.T. and Powell, J.D. (2012) mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol. Rev. 249, 43-58
10. Halestrap, A.P. (2013) The SLC16 gene family - structure, role and regulation in health and disease. Mol. Aspects Med. 34, 337-349
11. Dhup, S., Dadhich, R.K., Porporato, P.E. and Sonveaux, P. (2012) Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr. Pharm. Des. 18, 1319-1330
12. Roland, C.L., Arumugam, T., Dang, D., Liu, S.H., Philip, B., Gomez, S., Burns, W.R., Ramachandran, V., Wang, H., Cruz-Monserrate, Z. and Logsdon, C.D. (2014) Cell surface lactate receptor GPR81 is crucial for cancer cell survival. Cancer Res. 74, 5301-5310
13. Staubert, C., Broom, O.J. and Nordstrom, A. (2015) Hydroxycarboxylic acid receptors are essential for breast cancer cells to control their lipid/fatty acid metabolism. Oncotarget 6, 19706-19720
14. Di Cosimo, S., Ferretti, G., Papaldo, P., Carlini, P., Fabi, A. and Cognetti, F. (2003) Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc) 39, 157-174
15. Cervantes-Madrid, D., Romero, Y. and Duenas-Gonzalez, A. (2015) Reviving lonidamine and 6-diazo-5-oxo-L-norleucine to be used in combination for metabolic cancer therapy. Biomed. Res. Int. 2015, 690492
16. Floridi, A., Paggi, M.G., D'Atri, S., De Martino, C., Marcante, M.L., Silvestrini, B. and Caputo, A. (1981) Effect of lonidamine on the energy metabolism of Ehrlich Ascites tumor cells. Cancer Res. 41, 4661-4666
17. Mathupala, S.P., Ko, Y.H. and Pedersen, P.L. (2009) Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for cancer therapy. Semin. Cancer Biol. 19, 17-24
18. Shoshan-Barmatz, V., Ben-Hail, D., Admoni, L., Krelin, Y. and Tripathi, S.S. (2015) The mitochondrial voltage-dependent anion channel 1 in tumor cells. Biochim. Biophys. Acta 1848, 2547-2575
19. Bonora, M. and Pinton, P. (2014) The mitochondrial permeability transition pore and cancer: molecular mechanisms involved in cell death. Front. Oncol. 4, 302
20. Tsujimoto, Y. and Shimizu, S. (2007) Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 12, 835-840
21. Ravagnan, L., Marzo, I., Costantini, P., Susin, S.A., Zamzami, N., Petit, P.X., Hirsch, F., Goulbern, M., Poupon, M.F., Miccoli, L. et al. (1999) Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 18, 2537-2546
22. Floridi, A. and Lehninger, A.L. (1983) Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Arch. Biochem. Biophys. 226, 73-83
23. Guo, L., Shestov, A.A., Worth, A.J., Nath, K., Nelson, D.S., Leeper, D.B., Glickson, J.D. and Blair, I.A. (2016) Inhibition of mitochondrial complex II by the anticancer agent lonidamine. J. Biol. Chem. 291, 42-57
24. Nancolas, B., Guo, L., Zhou, R., Nath, K., Nelson, D.S., Leeper, D.B., Blair, I.A., Glickson, J.D. and Halestrap, A.P. (2016) The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem. J., in the press
25. Bricker, D.K., Taylor, E.B., Schell, J.C., Orsak, T., Boutron, A., Chen, Y.C., Cox, J.E., Cardon, C.M., Van Vranken, J.G., Dephoure, N. et al. (2012) A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 337, 96-100
26. Young, C.W., Currie, V.E., Kim, J.H., O'Hehir, M.R., Farag, F.M. and Kinahan, J.E. (1984) Phase I and clinical pharmacologic evaluation of lonidamine in patients with advanced cancer. Oncology 41 Suppl 1, 60-65
27. Newell, D.R., Mansi, J., Hardy, J., Button, D., Jenns, K., Smith, I.E., Picollo, R. and Catanese, B. (1991) The pharmacokinetics of oral lonidamine in breast and lung cancer patients. Semin. Oncol. 18 2 Suppl 4, 11-17
28. Karunakaran, S., Umapathy, N.S., Thangaraju, M., Hatanaka, T., Itagaki, S., Munn, D.H., Prasad, P.D. and Ganapathy, V. (2008) Interaction of tryptophan derivative with SLC6A14 (ATB0,+ ) reveals the potential of the transporter as a drug target for cancer chemotherapy. Biochem. J. 414, 343-355
29. Saunier, E., Benelli, C. and Bortoli, S. (2016) The pyruvate dehydrogenase complex in cancer: an old metabolic gatekeeper regulated by new pathways and pharmacological agents. Int. J. Cancer 138, 809-817
30. Kankotia,S. Stacpoole,P.W.2014Dichloroacetate and cancer: New home for an orphan drug?Biochim. Biophys. Acta1846617-629
31. Gill, A.J. (2012) Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology 44, 285-292